News

Latest news

Hide mandatory notifications of trade

GLOBVAC Grant to Bionor Pharma to Advance Research on Vacc-HIV, a Combination of Vacc-4x and Vacc-C5

Oslo 21.06.2013 - Bionor Pharma ASA (OSE: BIONOR) announced today that the Research Council of Norway through its GLOBVAC program (for Global Health and Vaccine Research) has awarded Bionor Pharma partial funding for preclinical studies and a phase I/II clinical trial on Vacc-HIV, a combination of Vacc-4x and Vacc-C5.

Award Represents a Potential Vital Step to Research Future Solutions for People Living with HIV

Bionor Pharma ASA (OSE: BIONOR) announced today that the Research Council of Norway through its GLOBVAC program (for Global Health and Vaccine Research) has awarded Bionor Pharma partial funding for preclinical studies and a phase I/II clinical trial  on Vacc-HIV, a combination of Vacc-4x and Vacc-C5. These studies will provide important information to support the development of Vacc-HIV, a therapeutic HIV vaccine that could contribute to the future management of HIV infection and  ultimately allow for a Functional Cure, which may enable  people  to live long-term with no disease progression nor viral transmission in the absence of ongoing antiretroviral therapy (conventional HIV medication).

The grant is titled “Vacc-HIV: A novel therapeutic vaccine combination for HIV infection.”
The amount granted will be announced at a later stage.

About GLOBVAC
Research Council of Norway’s Programme for Global Health and Vaccine Research, GLOBVAC, supports research that can contribute to sustainable improvements in health and health equity for people in low- and middle-income countries.

The program has a wide scope, and gives highest priority to projects in the following thematic areas: Vaccine- and vaccination research; Health systems and health policy research; Innovation in technology- and methods development; Implementation research.

The annual budget of the GLOBVAC program is currently NOK 60.8 mill. (US$11.3 million).

Bionor Pharma ASA

Hilde Aalling Syvertsen,
-Director Communications & Corporate Affairs 

Tel +47 23 01 09 60

About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.

Global leader in the development of HIV vaccines
The Company has a leading position in the global research field for therapeutic HIV vaccines, and has two vaccine candidates in the clinical stage of development: Vacc-4x aims to induce long lasting virus control by training immune cells to seek out and kill virus-producing cells, and Vacc-C5 is designed to induce antibodies to HIV that can reduce the harmful hyperactivation of the immune system which can lead to AIDS. The foremost candidate, Vacc-4x, has shown a statistically significant reduction in viral load in a phase II randomized, multinational, double-blind, placebo-controlled study. The Company’s innovative technology platform is also well positioned to develop vaccines for other viral diseases, such as Influenza, HCV (Hepatitis C), HPV (Human papillomavirus) and CMV (Cytomegalovirus).


This information is subject to the disclosure requirements of §5-12 vphl
(Norwegian Securities Trading Act).  Vacc-4x, Vacc-C5, Vacc-HIV, Vacc-Flu, Vacc-HCV, Vacc-CMV and Vacc-HPV are currently investigational treatments that have not been approved for marketing by any regulatory authority.